Sucholeiki相关文献与解析，生知库 | 链接生命科学的每一步

ALS Patients Exhibit Altered Levels of Total and Active MMP-9 and Several Other Biomarkers in Serum and CSF Compared to Healthy Controls and Other Neurologic Diseases

与健康对照组和其他神经系统疾病患者相比，ALS患者血清和脑脊液中总MMP-9和活性MMP-9以及其他几种生物标志物的水平发生改变。

期刊:International Journal of Molecular Sciences

影响因子:4.9

doi:10.3390/ijms26188900

Bowser, Robert; An, Jiyan; Schwartz, Kimberly; Sucholeiki, Robert L; Sucholeiki, Irving

Intermittent fasting and its impact on toxicities, symptoms and quality of life in patients on active cancer treatment

间歇性禁食及其对正在接受癌症治疗的患者的毒性、症状和生活质量的影响

期刊:Cancer Treatment Reviews

影响因子:10.5

doi:10.1016/j.ctrv.2024.102725

Li Sucholeiki, Robert; Propst, Casey L; Hong, David S; George, Goldy C

Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes

利用无细胞DNA收集管检测非小细胞肺癌患者血浆无细胞DNA中EGFR突变的基于聚合酶链式反应的检测方法的性能特征

期刊:PLoS One

影响因子:2.6

doi:10.1371/journal.pone.0295987

May, Theresa; Clement, Michelle S; Halait, Harkanwal; Kohlmann, Alexander; Kohlmann, Milena; Lai, Jason; Lee, Nitta; Li-Sucholeiki, Xiaocheng; Meldgaard, Peter; Joshi, Snehal; Scudder, Sidney; Shrestha, Neelima; Sorensen, Boe; Kiral, Marilyn; O'Donnell, Patrick

Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor for the treatment of Osteoarthritis

开发用于治疗骨关节炎的选择性基质金属蛋白酶 13 (MMP-13) 抑制剂

期刊:European Journal of Medicinal Chemistry

影响因子:6

doi:10.1016/j.ejmech.2021.113666

Alison M Bendele, Madhavi Neelagiri, Venugopal Neelagiri, Irving Sucholeiki

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)

针对携带 EGFR 敏感突变且一线奥希替尼治疗后病情进展的晚期/转移性非小细胞肺癌患者的生物标志物导向 II 期平台研究 (ORCHARD)

期刊:Clinical Lung Cancer

影响因子:3.3

doi:10.1016/j.cllc.2021.06.006

Yu, Helena A; Goldberg, Sarah B; Le, Xiuning; Piotrowska, Zofia; Goldman, Jonathan W; De Langen, Adrianus J; Okamoto, Isamu; Cho, Byoung Chul; Smith, Paul; Mensi, Ilhem; Ambrose, Helen; Kraljevic, Silvija; Maidment, Julie; Chmielecki, Juliann; Li-Sucholeiki, Xiaocheng; Doughton, Gail; Patel, Gargi; Jewsbury, Phil; Szekeres, Phil; Riess, Jonathan W

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

FLAURA试验中组织和血浆EGFR突变分析：奥希替尼与对照EGFR酪氨酸激酶抑制剂作为EGFR突变晚期非小细胞肺癌患者一线治疗的比较

期刊:Clinical Cancer Research

影响因子:10.2

doi:10.1158/1078-0432.CCR-19-1126

Gray, Jhanelle E; Okamoto, Isamu; Sriuranpong, Virote; Vansteenkiste, Johan; Imamura, Fumio; Lee, Jong Seok; Pang, Yong-Kek; Cobo, Manuel; Kasahara, Kazuo; Cheng, Ying; Nogami, Naoyuki; Cho, Eun Kyung; Su, Wu Chou; Zhang, Guili; Huang, Xiangning; Li-Sucholeiki, Xiaocheng; Lentrichia, Brian; Dearden, Simon; Jenkins, Suzanne; Saggese, Matilde; Rukazenkov, Yuri; Ramalingam, Suresh S

Biomarker Analysis of Orally Dosed, Dual Active, Matrix Metalloproteinase (MMP)-2 and MMP-9 Inhibitor, AQU-118, in the Spinal Nerve Ligation (SNL) Rat Model of Neuropathic Pain.

在脊神经结扎 (SNL) 大鼠神经病理性疼痛模型中，对口服双重活性基质金属蛋白酶 (MMP)-2 和 MMP-9 抑制剂 AQU-118 进行生物标志物分析

期刊:International Journal of Molecular Sciences

影响因子:4.9

doi:10.3390/ijms20040811

Kwan Mei Yee, Choo Anthony, Hanania Taleen, Ghavami Afshin, Beltran Jose, Shea John, Barboza Amidi, Hu Andrew, Fowler Marcie, Neelagiri Venugopal Rao, Sucholeiki Irving

Analysis of mutational spectra by denaturing capillary electrophoresis

变性毛细管电泳法分析突变谱

期刊:Nature Protocols

影响因子:13.1

doi:10.1038/nprot.2008.79

Per O Ekstrøm, Konstantin Khrapko, Xiao-Cheng Li-Sucholeiki, Ian W Hunter, William G Thilly

信号转导

发表日期：2008

文献求助收藏

A sensitive scanning technology for low frequency nuclear point mutations in human genomic DNA

一种用于检测人类基因组DNA中低频核点突变的灵敏扫描技术

期刊:Nucleic Acids Research

影响因子:13.1

doi:10.1093/nar/28.9.e44

Li-Sucholeiki, X C; Thilly, W G

发表日期：2000

文献求助收藏

ADPKD Progression by Variant Type and Molecular Domain Among Participants in the HALT PKD Trial

HALT PKD试验参与者中ADPKD按变异类型和分子结构域划分的进展情况

ALS Patients Exhibit Altered Levels of Total and Active MMP-9 and Several Other Biomarkers in Serum and CSF Compared to Healthy Controls and Other Neurologic Diseases

与健康对照组和其他神经系统疾病患者相比，ALS患者血清和脑脊液中总MMP-9和活性MMP-9以及其他几种生物标志物的水平发生改变。

Intermittent fasting and its impact on toxicities, symptoms and quality of life in patients on active cancer treatment

间歇性禁食及其对正在接受癌症治疗的患者的毒性、症状和生活质量的影响

Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes

利用无细胞DNA收集管检测非小细胞肺癌患者血浆无细胞DNA中EGFR突变的基于聚合酶链式反应的检测方法的性能特征

Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor for the treatment of Osteoarthritis

开发用于治疗骨关节炎的选择性基质金属蛋白酶 13 (MMP-13) 抑制剂

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)

针对携带 EGFR 敏感突变且一线奥希替尼治疗后病情进展的晚期/转移性非小细胞肺癌患者的生物标志物导向 II 期平台研究 (ORCHARD)

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

FLAURA试验中组织和血浆EGFR突变分析：奥希替尼与对照EGFR酪氨酸激酶抑制剂作为EGFR突变晚期非小细胞肺癌患者一线治疗的比较

Biomarker Analysis of Orally Dosed, Dual Active, Matrix Metalloproteinase (MMP)-2 and MMP-9 Inhibitor, AQU-118, in the Spinal Nerve Ligation (SNL) Rat Model of Neuropathic Pain.

在脊神经结扎 (SNL) 大鼠神经病理性疼痛模型中，对口服双重活性基质金属蛋白酶 (MMP)-2 和 MMP-9 抑制剂 AQU-118 进行生物标志物分析

Analysis of mutational spectra by denaturing capillary electrophoresis

变性毛细管电泳法分析突变谱

A sensitive scanning technology for low frequency nuclear point mutations in human genomic DNA

一种用于检测人类基因组DNA中低频核点突变的灵敏扫描技术